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Objectives The aim of this work was to comprehensively study the role of platelets in atrial fibrillation (AF), in relation to the
underlying cardiovascular diseases and type of AF, and to analyze the effect of antithrombotic treatment on dif-
ferent aspects of platelet activation.
Background Platelet activation is present in nonvalvular AF, but there is debate whether this is due to AF itself and/or to un-
derlying cardiovascular diseases.
Methods A total of 121 AF patients were compared with 65 “healthy control subjects” and 78 “disease control subjects”
in sinus rhythm. Platelet activation was assessed using 4 different aspects of platelet pathophysiology: 1) plate-
let surface expression of CD62P (P-selectin) and CD63 (a lysosomal glycoprotein) (by flow cytometry); 2) mean
platelet volume (MPV) (by flow cytometry); 3) plasma levels of soluble P-selectin (sP-selectin, enzyme-linked
immunoadsorbent assay); and 4) total amount of P-selectin per platelet (pP-selectin) (“platelet lysis” assay).
Results Both AF patients and “disease control subjects” had higher levels of CD62P (p  0.001), CD63 (p  0.001), and
sP-selectin (p  0.001) compared with “healthy control subjects,” with no difference between AF patients and
“disease control subjects.” Patients with permanent AF had higher levels of sP-selectin (p  0.014) and MPV
(p  0.025) compared with those with paroxysmal AF. The presence of AF independently affected the levels of
CD62P expression, while “high-risk” AF patients (CHADS score 2) had higher levels of CD62P compared with
those with “low risk.” Introducing warfarin resulted in a reduction of pP-selectin (p  0.013).
Conclusions There is a degree of excess of platelet activation in AF compared with “healthy control subjects,” but no signifi-
cant difference between AF patients and “disease control subjects” in sinus rhythm. Platelet activation may dif-
fer according to the subtype of AF, but this is not in excess of the underlying comorbidities that lead to AF.
Platelet activation in AF may be due to underlying cardiovascular diseases, rather than due to AF per se.
(J Am Coll Cardiol 2007;49:1957–64) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.038a
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aonvalvular atrial fibrillation (AF) is associated with an
pproximately 5-fold increase in stroke risk, which is higher
n association with clinical and echocardiographic variables
1,2). The pathophysiology of thromboembolism in AF
s multifactorial, but increasing evidence points to the
ulfillment of Virchow’s triad, with flow abnormalities,
bnormalities of the vessel wall (endothelial/endocardial
bnormalities), and abnormal blood constituents (platelets
rom the Haemostasis Thrombosis and Vascular Biology Unit, University Depart-
ent of Medicine, City Hospital, Birmingham, United Kingdom.a
Manuscript received November 27, 2006; revised manuscript received January 29,
007, accepted February 5, 2007.nd the clotting cascade) present, resulting in a prothrom-
otic/hypercoagulable state (3).
Platelets play a role in rendering AF more “prothrom-
otic” by interacting with the endothelium, proteins of the
oagulation cascade, and inflammatory cells (e.g., mono-
ytes) (4). On activation, the normal platelet undergoes a
eries of characteristic changes that include shape change,
embrane budding, adhesion, aggregation, release of gran-
lar contents, and thromboxane synthesis. Methods aimed
t measuring platelet activation detect these changes either
irectly or indirectly. For example, direct assays (e.g.,
lectron microscopy, flow cytometry) allow platelets to be
ssessed in their physiological milieu of whole blood, and
re extremely sensitive, with the ability to detect as few as
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Hence, such methods are partic-
ularly useful in monitoring rapid
changes of activation status, but,
in order to prevent/minimize ar-
tifactual platelet activation, blood
has to be collected with minimal
stasis and analyzed promptly (6).
In contrast, “indirect” assays
mostly measure the metabolites
of activated platelets in the
plasma or urine (e.g., enzyme-
linked immunoadsorbent assay
[ELISA]). In general, as these
metabolites are modified in vivo
before assay, and these assays are
arguably not as sensitive in de-
tecting dynamic changes as the
“direct” assays, but at the same
time are less prone to be affected
by artifactual platelet activation
during blood collection. Hence,
hey are more useful in measuring “baseline” platelet
ctivation.
Thus, different platelet assays assess different aspects of
latelet pathophysiology, and the results depend on the
linical condition being investigated and the aspect of
latelet activation being measured. Unfortunately, there is
o consensus on the best method of measuring platelet
ctivation, and an “ideal” study of platelet activation should
nclude at least 1 of each of the “direct” and “indirect” assays.
lthough there are numerous studies assessing platelet
ctivation in AF, the results are (unsurprisingly) inconsis-
ent, thus reflecting difference between the assays and the
ifferent aspects of platelet function measured (7–12).
The possibility also arises that platelet activation differs in
F depending on the type of AF and the use of antithrom-
otic therapy (13–15). It also remains unclear to what extent
latelet activation in AF is due to AF itself and/or to the
nderlying cardiovascular diseases (e.g., coronary artery
isease [CAD], hypertension, diabetes, and stroke).
The aim of the present study was to comprehensively
tudy the role of platelets in AF, especially in relation to the
nderlying cardiovascular diseases, type of AF, and to
nalyze the effect of antithrombotic treatment on different
spects of platelet activation. To achieve this, AF patients
ere compared not only with “healthy control subjects,” but
lso with “disease control subjects” (in sinus rhythm).
latelet activation was assessed by looking into 4 different
spects of platelet pathophysiology: 1) platelet surface ex-
ression of CD62P (P-selectin) and CD63 (lysosomal
lycoprotein) (using flow cytometry); 2) mean platelet
olume (MPV) (flow cytometry); 3) plasma levels of soluble
-selectin (sP-selectin) (ELISA); and 4) total amount of
-selectin per platelet (pP-selectin) (as quantified with a
Abbreviations
and Acronyms
AF  atrial fibrillation
CAD  coronary artery
disease
ELISA  enzyme-linked
immunoadsorbent assay
MPV  mean platelet
volume
PAF  paroxysmal atrial
fibrillation
PBS  phosphate-buffered
solution
PFP  platelet-free plasma
pP-selectin  total amount
of P-selectin per platelet
PRP  platelet-rich plasma
sP-selectin  soluble
P-selectin
TG  beta-thromboglobulinplatelet lysis” assay). iethods
utpatients attending our AF clinic in our hospital were
nvited to participate in our study. All had AF diagnosed on
lectrocardiogram before recruitment. Exclusion criteria for
he study included refusal of consent, any history of malig-
ancy, connective tissue disease, thyroid disease, renal dis-
ase, use of steroids, hormone replacement therapy, active
moking, and any concomitant “active/acute” cardiovascular
isease. “Disease control subjects” were recruited from patients
ttending our CAD, hypertension, and general cardiology
linics. “Healthy control subjects” were normotensive and in
inus rhythm, who were not taking regular medications and
ad no evidence of disease on careful history, clinical exami-
ation, and basic blood tests. To assess the effect of antithrom-
otic therapy, we also recruited AF patients whose antithrom-
otic treatment was changed from aspirin to warfarin. Paired
ata from these patients were used to determine the effect of
ntithrombotic treatment on indexes of platelet activation.
lood collection. Blood was collected according to the
ethod described in the European Working Group on
linical Analysis Consensus Protocol on platelet flow cy-
ometry (6): 25 ml of blood was taken from an antecubital
ein with minimal stasis into vacutainers tubes (BD Bio-
ciences, Oxford, United Kingdom). Aliquots of blood were
ollected into citrated (containing 0.5 ml of 3.8% sodium
itrate) and CTAD (containing citrate, theophylline, aden-
sine, and dipyridamole) vacutainers. The citrated samples
ere to be used for platelet lysate assay and measuring
lasma levels of sP-selectin, while the CTAD samples were
sed for flow cytometric work.
low cytometry. Blood for platelet flow cytometry was
ollected as described in the preceding text (6). CaliBRITE
-color beads and FACSComp software (BD Biosciences)
ere used to set photomultiplier tube voltages, fluorescence
ompensation, spectral overlap, and sensitivity. Size-
ependent forward scatter and 90° side scatter were set at
ogarithmic gain. Mouse IgG2a and IgG1 antikeyhole limpet
emocyanin monoclonal antibodies conjugated to phyco-
rythrin were used as isotype-negative controls to define
onspecific binding. Monoclonal antibodies were obtained
rom BD Biosciences. Data acquisition and analysis were
erformed with CELLQuest software version 3.1 in the
ow cytometer (FACScan, BD Biosciences).
Flow cytometric analysis was commenced within 15 min
f blood collection, to prevent artificial elevated levels
econdary to in-vitro platelet activation; 100 l of the
TAD sample was diluted with 800 l of phosphate-
uffered solution (PBS). Two separate aliquots of 15 l of
his diluted sample were then incubated with 10 l of
nti–CD42b-FITC (binds to platelet glycoprotein 1b) and
0 l of anti–CD62P-PE (binds to platelet membrane
ound P-selectin) or anti–CD63-PE (binds to platelet
ysosomal membrane glycoprotein). After incubation for 30
in, the samples were further diluted with 800 l of PBS
mmediately before flow cytometric analysis. Results were
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May 15, 2007:1957–64 Platelets in Atrial Fibrillationxpressed as the percentage of CD62P- or CD63-positive
vents compared with the total number of CD42b-positive
vents. The inter- and intra-assay coefficients of variation
ere 5% and 8%, respectively.
latelet lysate. The mass of pP-selectin per platelet (i.e.,
latelet P-selectin/pP-selectin) was measured using a
platelet lysate assay,” as follows: platelet-rich plasma (PRP)
as obtained by centrifugation of citrated blood within 15
in of collection, at 1,000 rpm for 10 min; 1 ml of the PRP
as centrifuged for a further 20 min at 3,000 rpm to obtain
platelet pellet. The supernatant (platelet-free plasma
PFP]) was stored at 70°C for measurement of plasma
evels of sP-selectin by ELISA.
The concentration of platelets (from the PRP) was
etermined using ADVIA 120 hematology system (Bayer,
ewbury, United Kingdom). Accordingly, the platelet pel-
et was resuspended in saline to achieve a fixed concentra-
ion of 200  106 platelets per ml, and then lysed with an
qual volume of 0.1% Triton X-100 (Sigma/Aldrich, Poole,
orset, United Kingdom). Aliquots were stored at 70°C
o allow batch analysis of pP-selectin by ELISA. The inter-
nd intra-assay coefficients of variation were 5% and 10%,
espectively.
LISA for P-selectin. Levels of sP-selectin (1/5 dilution
f plasma) from the PFP and pP-selectin (1/10 dilution)
rom the lysed platelet sample were derived from standard
urves using the commercial ELISA kit from R&D Systems
Abingdon, Oxon, United Kingdom). The inter- and intra-
ssay coefficient of variation were 5% and 10%, respec-
ively. The lower limit of sensitivity of the assay was 0.8
g/ml.
ower calculation. Previous data on markers of platelet
ctivation reveal that some are normally distributed (14–17)
hile others have a non-normal distribution (13,15,18). We
ypothesized that indexes of platelet activation will be
levated by: 1) 0.25 of a SD for indexes normally distributed
nd by 50% of the median values in indexes non-normally
istributed, in “disease control subjects” compared with
healthy control subjects”; and by 2) 0.5 SD and 100% of the
edian in AF patients compared with “healthy control
ubjects.” Using sP-selectin as the reference molecule, to
chieve a difference of p  0.05 and a power of 0.80, we
equired 60 recruits in each group. We therefore recruited
onsecutive patients and controls until we had 60 in each
roup and then exceeded it for extra confidence. We also
ypothesized that levels of indexes of platelet activation will
ntercorrelate with sP-selectin, to a degree of a Spearman’s
ank correlation of at least 0.4, which we consider as
ignificant.
ata analysis and statistics. After application of Anderson-
arling test, normally distributed data were expressed as
ean (SD), while non-normally distributed data were
xpressed as median (interquartile range). Categorical data
ere analyzed by chi-square test. Differences between
roups were analysed by Kruskal-Wallis test (for non-
ormally distributed data) or 1-way analysis of variance (for wormally distributed data). For intergroup differences,
ukey’s post hoc test was used, using log-transformed data
here appropriate. As all research indexes other than MPV
ere non-normally distributed, all correlations were accord-
ng to Spearman’s rank correlation method. Stepwise mul-
iple regression analysis on the combined cohort of AF and
disease control subjects” was performed to determine
hether the presence/absence of AF and other clinical
eatures (again, on log-transformed data where appropriate)
as independently predictive of the levels of the platelet
arkers under investigation. A probability of 0.05 was
onsidered statistically significant.
esults
e invited 150 consecutive patients with AF to participate
n our study. Of these, 9 declined our invitation while
nother 20 could not be recruited because of our exclusion
riteria. Thus, we recruited a total of 121 patients with AF
58 paroxysmal AF [PAF] and 63 permanent AF) and
ompared them with 78 “disease control subjects” and 65
healthy control subjects” (Table 1). There were no signif-
cant differences in underlying cardiovascular comorbidities
nd antiplatelet drug usage between the AF patients and
disease control subjects.”
ross-sectional analyses. Both AF patients and “disease
ontrol subjects” had higher levels of CD62P (p  0.001),
D63 (p  0.001), and sP-selectin (p  0.001) compared
ith “healthy control subjects.” There were no differences
etween AF patients and “disease control subjects” with
egards to the markers as discussed earlier (Table 2).
lthough AF patients had higher levels of pP-selectin
ompared with both “healthy” and “disease control sub-
ects,” this did not achieve significance (p  0.118) (Table
). There was no difference in MPV between the 3 groups
p  0.213) (Table 2).
Among AF patients, those with permanent AF had more
ssociated cardiovascular disease (87.3% vs. 61.4%; p 
.001), as well as significantly higher levels of sP-selectin
p  0.014) and MPV (p  0.025) compared with those
ith PAF (Table 3, top). Though permanent AF patients
lso had higher levels of CD62P, CD63, and pP-selectin
ompared with PAF patients, these small differences were
ot statistically significant (Table 3, top). There were no
ignificant differences in any of the platelet indexes among
F patients on aspirin compared with those on warfarin
Table 3, middle). Atrial fibrillation patients with a higher
isk of stroke (CHADS2 score of 2) (19,20) had higher
evels of CD62P (p  0.003) and lower MPV (p  0.020)
ompared with “low-risk” AF patients. There were differ-
nces in CD63, sP-selectin, and pP-selectin levels between
he 2 groups (Table 3, bottom).
ffect of introducing antithrombotic treatment. To de-
ermine the effects of antithrombotic treatment on the
ndexes of platelet activation, we recruited 11 AF patients
hose antithrombotic therapy was changed from aspirin to
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Platelets in Atrial Fibrillation May 15, 2007:1957–64arfarin (as per clinical risk stratification). Switching to
arfarin therapy was associated with a reduction in the total
mount of pP-selectin (p  0.013) along with nonsignifi-
ant reductions of CD62P and CD63 expression on plate-
ets and in the total amount of sP-selectin in the plasma
Table 4).
orrelations. Platelet expression of CD62P and CD63
ad a strong positive correlation (r  0.6; p  0.001 in all
groups). Among “disease control subjects,” CD62P ex-
aseline Characteristic in Nonvalvular AF Patients and Control Sub
Table 1 Baseline Characteristic in Nonvalvular AF Patients and
“Healthy Control Subjects” “Disease Cont
Numbers 65 78
Age in years 61.02 (10.97) 64.06 (1
Male gender, n (%) 43 (66.2) 57 (7
BMI 26.5 (3.7) 27.8 (3
SBP 133.3 (13.1) 138.9 (1
DBP 78.3 (8.5) 80.2 (9
Cholesterol (mmol/l) 5.5 (0.8) 4.6 (1
WBC (103/mm3) 6.4 (1.7) 7.1 (2
Hb (g%) 14.0 (1.2) 13.9 (1
Hct (%) 40.6 (33.7) 41.6 (3
Platelets (108/mm3) 266.9 (56.1) 261.1 (6
Comorbidities
IHD, n (%) — 22 (2
HT, n (%) — 54 (6
CVA/TIA, n (%) — 6 (7
DM, n (%) — 10 (1
PVD, n (%) — 1 (1
Treatment
Warfarin, n (%) — 5 (6
Aspirin, n (%) — 37 (4
Clopidogrel, n (%) — 9 (1
ACEI or ARB, n (%) — 45 (5
Diuretics, n (%) — 23 (3
CCB, n (%) — 20 (2
Beta-blocker, n (%) — 34 (4
Statin, n (%) — 50 (6
alues are expressed as mean (SD) or number (%). Analyses done by chi-square test (for categoric
ntergroup differences with Tukey’s test (p  0.05): *difference lies between “healthy” and “diseas
etween “disease control subjects” and AF patients.
ACEI  angiotensin-converting enzyme inhibitor; AF  atrial fibrillation; ARB  angiotensin rece
BP  diastolic blood pressure; DM  diabetes mellitus; Hb  hemoglobin; Hct  hematocrit; HT
ressure; TIA  transient ischemic attack; WBC  white blood cell.
ndexes of Platelet Activation in Patients With AF Compared With
Table 2 Indexes of Platelet Activation in Patients With AF Com
Marker of Platelet Activation “Healthy Control Subjects” “Disease Cont
n 65 7
CD62P (% gated) 1.21 (0.69–2.17) 1.71 (1.0
CD63 (% gated) 4.68 (2.10–6.62) 5.26 (3.1
sP-selectin (ng/ml) 40 (30–50) 57 (36
Lysate P-selectin (ng/ml) 300 (180–420) 320 (19
MPV (fl) 7.39 (0.96) 7.76 (0
alues are expressed as mean (SD) or median (1st–3rd interquartile range) and analyzed by 1-
og-transformed data) where appropriate. Significant p values are indicated in bold. Intergroup dif
difference lies between “healthy control subjects” and atrial fibrillation (AF) patients.
MPV  mean platelet volume; sP-selectin  soluble P-selectin.ression negatively correlated with pP-selectin (r  0.34;
 0.005) and MPV (r  0.26; p  0.046). These
egative correlations were also noted among the other 2
roups, but they were not statistically significant. No sig-
ificant correlations were found between sP-selectin and
D62P expression or pP-selectin, in any of the 3 groups.
Stepwise multiple regression analysis on the combined
ohort of AF and “disease control subjects” revealed that
resence of AF was independently associated with CD62P
trol Subjects
jects” AF Patients
p Value (“Healthy Control Subjects” vs.
“Disease Control Subjects” vs. AF Patients)
121 —
62.58 (8.6) 0.176
91 (76.0) 0.355
27.1 (3.9) 0.144
133.3 (14.4) 0.013*
78.8 (9.2) 0.439
4.8 (0.9) 0.001*†
7.1 (1.7) 0.07
14.6 (1.6) 0.007‡
42.3 (4.3) 0.316
259.9 (66.3) 0.811
29 (23.9) 0.001*†
77 (63.6) 0.001*†
12 (10.0) 0.034†
10 (8.2) 0.014*
2 (1.7) 0.587*
54 (44.6) 0.001†‡
46 (37.2) 0.001*†
7 (5.8) 0.015*
65 (53.7) 0.001*†
43 (35.5) 0.001*†
46 (38.0) 0.001*†
53 (43.8) 0.001*†
35 (28.9) 0.001*†‡
) or 1-way analysis of variance (for continuous data) and Tukey’s post hoc test where appropriate.
ol subjects”; †difference lies between “healthy control subjects” and AF patients; ‡difference lies
cker; BMI  body mass index; CCB  calcium-channel blocker; CVA  cerebrovascular accident;
rtension; IHD  ischemic heart disease; PVD  peripheral vascular disease; SBP  systolic blood
lthy” and “Disease Control Subjects”
d With “Healthy” and “Disease Control Subjects”
bjects” AF Patients
p Value (“Healthy Control Subjects” vs.
“Disease Control Subjects” vs. AF Patients)
121 —
0) 2.43 (1.30–5.32) <0.001*†
4) 6.08 (3.94–10.72) <0.001*†
59 (42–84) <0.001*†
) 380 (227–600) 0.118
7.56 (1.38) 0.213
lysis of variance or Kruskal-Wallis test, with intergroup differences by Tukey’s post hoc test (on
s with Tukey’s test (p  0.05): *difference lies between “healthy” and “disease control subjects”;jects
Con
rol Sub
0.29)
3.1)
.7)
3.9)
.8)
.4)
.1)
.6)
.9)
3.5)
8.2)
9.2)
.7)
2.8)
.2)
.4)
7.4)
1.5)
7.7)
0.8)
5.6)
3.6)
4.1)
al data
e contr
ptor blo“Hea
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rol Su
8
0–3.8
7–9.3
–74)
5–540
.98)
way ana
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May 15, 2007:1957–64 Platelets in Atrial Fibrillationxpression (p  0.029), but not CD63 expression (p 
.166), sP-selectin (p  0.097), pP-selectin (p  0.397), or
PV (p  0.288).
iscussion
ur results suggest that there is excess of platelet activation
n AF patients compared with “healthy control subjects” as
easured by sP-selectin levels and expression of CD62P
nd CD63, but not in terms of total amount of pP-selectin
nd MPV. However, there was no excess of platelet activa-
Assessment of Platelet Activation Among AF Pa
Table 3 Assessment of Platelet Activation A
Between Paroxysmal a
Marker of Platelet Activation Paroxysmal
Numbers 58
CD62P (% gated) 2.43 (1.04–5.
CD63 (% gated) 5.58 (3.47–10
sP-selectin (ng/ml) 51 (38–70)
Lysate P-selectin (ng/ml) 340 (220–48
MPV (pg) 7.27 (0.79)
Aspirin and War
Marker of Platelet Activation AF Patients on
Numbers 49
CD62P (% gated) 2.42 (1.13–5
CD63 (% gated) 6.24 (4.00–9
sP-selectin (ng/ml) 54 (42–72)
Lysate P-selectin (ng/ml) 410 (258–54
MPV (pg) 7.38 (0.90)
Between High-Risk (CHADS Score >2) a
Marker of Platelet Activation CHADS Score
Numbers 80
CD62P (% gated) 1.92 (1.05–4.
CD63 (% gated) 6.37 (4.92–11
sP-selectin (ng/ml) 55 (39–78)
Lysate P-selectin (ng/ml) 390 (248–62
MPV (pg) 7.76 (1.51)
Values are expressed as mean (SD) or median (1st–3rd interquartile
are indicated in bold. *Paroxysmal AF was defined as patients with d
while permanent AF was defined where AF was present for1 year an
Abbreviations as in Table 2.
ffect of Aspirin or Warfarin Therapyn Platelet Activation in Atrial Fibrillation
Table 4 Effect of Aspirin or Warfarin Therapyon Platelet Activation in Atrial Fibrillation
Platelet Marker On Aspirin
4 Weeks After
Swapping to Warfarin p Value
Numbers 11 11 —
CD62P (% gated) 3.62 (1.62–6.38) 3.31 (1.08–3.73) 0.554
CD63 (% gated) 5.61 (3.93–7.04) 4.75 (2.35–11.01) 0.676
sP-selectin (ng/ml) 54 (43–74) 48 (42–64) 0.906
Lysate P-selectin
(ng/ml)
503 (340–1,038) 360 (190–400) 0.013
MPV (pg) 7.36 (1.01) 7.36 (1.41) 0.829
alues expressed as median (interquartile range); paired data analyzed by Wilcoxon (for non-
ormally distributed data) or paired t test (for normally distributed data). Significant p values areh
ndicated in bold.
MPV  mean platelet volume.ion (as measured by 4 different methods) in AF patients
ompared with “disease control subjects.” This is consistent
ith the view that platelet activation in AF is more related
o the associated vascular diseases, rather than the arrhyth-
ia itself. On a stepwise multiple regression analysis,
resence of AF did not significantly affect CD63, sP-
electin, pP-selectin, or MPV levels.
The role of platelets in atherothrombotic diseases is well
stablished (21). However, the relative significance of plate-
et activation in the overall atherothrombotic risk in differ-
nt cardiovascular diseases seems to vary. Although there is
vidence suggesting that platelets are activated in AF, the
vidence that it relates directly to the increased thrombotic
isk in AF is uncertain. Initial studies had reported associ-
tions between beta-thromboglobulin (TG) (a marker of
latelet activation) (22) and CD62P with intra-atrial
hrombus and echo-contrast (23). However, a subsequent
uch larger study (7) found no association between plasma
TG levels and subsequent thromboembolic events. Also,
lasma levels of sP-selectin were unrelated to estimated
troke risk (14), despite associations between sP-selectin
evels and atherothrombotic risk factors, such as smoking
nd peripheral vascular disease. Moreover, plasma markers
hat seem to have prognostic importance in identifying
s
g AF Patients
rmanent AF Patients*
Permanent AF p Value
63 —
2.50 (1.34–5.71) 0.926
6.69 (4.32–11.01) 0.208
64 (44–104) 0.014
400 (242–624) 0.216
7.84 (1.72) 0.025
se at Baseline
AF Patients on Warfarin p Value
54 —
2.50 (1.32–5.25) 0.798
6.63 (4.60–12.98) 0.219
61 (45–112) 0.146
315 (185–520) 0.086
7.46 (1.26) 0.697
w-Risk (CHADS Score <2) AF Patients
CHADS Score >2 p Value
41 —
3.78 (2.10–6.99) 0.003
5.79 (4.45–9.92) 0.792
64 (46–100) 0.115
380 (190–520) 0.346
7.20 (1.01) 0.020
and analyzed by Mann-Whitney or 2-sample t test. Significant p values
ted paroxysms of AF lasting 100 beats on 24-h Holter monitoring,
version was considered inappropriate or was previously unsuccessful.tient
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Platelets in Atrial Fibrillation May 15, 2007:1957–64rand factor) (14,24) are directly or indirectly linked to the
oagulation cascade rather than platelet activation per se.
nsurprisingly, the efficacy of warfarin in preventing the
ikelihood of strokes in AF is significantly superior not only
o aspirin (25) but also compared with the combination of
spirin and clopidogrel (26). Of note, the 22% risk reduc-
ion (of strokes) with aspirin just reaches statistical signifi-
ance, and it has been suggested to be secondary to the
eneficial role of aspirin on the underlying vascular disease
ather than on AF itself (25).
Over the last decade, the MPV has been established as a
imple and practical method of assessing platelet activation
n hypertension, CAD, diabetes, and stroke (16,17,27,28),
hich are all diseases that frequently coexist with AF.
mong patients with established cardiovascular diseases,
igher levels of MPV have been shown to identify “high-
isk” patients and those more likely to have poorer outcome
fter an acute vascular event (29–35). Until now, there have
een no previous reports on the behavior of MPV in
atients with nonvalvular AF, but the lack of significant
ifference in MPV between AF patients and “healthy
ontrol subjects” is in keeping with platelet activation
laying a secondary role in rendering AF more “pro-
hrombotic.”
The finding of no significant differences in pP-selectin
mong patients and control subjects could potentially be
xplained by 2 reasons. First, activated platelets result in
usion of -granules with the platelet surface, followed by
egranulation. This would explain higher levels of CD62P
nd sP-selectin in AF patients and “disease control subjects”
ompared with “healthy control subjects.” However, this
ery process might result in depletion of the total amount of
-selectin in the platelets, sufficient to render the difference
n pP-selectin statistically insignificant between the 3
roups. Second, it has been suggested that P-selectin,
xpressed on the surface of the platelet, changes its config-
ration upon platelet activation (36,37). Indeed, Semenov
t al. (38) demonstrated that the polyclonal antibody used in
heir study to detect sP-selectin in platelets had a lower
eactivity toward membrane P-selectin. As we have used the
LISA that detects sP-selectin, it is possible that the assay
ight have detected granular P-selectin, but not all of the
embrane expressed P-selectin.
Our finding of higher levels of sP-selectin in patients
ith permanent AF compared with those with PAF is in
eeping with previous reports (13). We also found higher
alues of MPV in permanent AF compared with PAF, but
o difference between the 2 groups with regards to platelet
embrane expression of CD62P and CD63, or pP-selectin
evels. It has been suggested that sP-selectin reflects back-
round chronic platelet activation, while CD62P expression
s associated with acute changes (39,40). Patients with
ermanent AF in our study had increased associated under-
ying cardiovascular disease compared with those with PAF,
nd it is possible that the associated comorbidities might
ave resulted in excess of background platelet activation, as fanifested by higher levels of sP-selectin and MPV in
ermanent AF.
Among the different platelet markers, CD62P and CD63
ere strongly correlated in all the 3 groups supporting the
oncept that platelet activation results in migration and
usion of  and lysosomal granules with the platelet mem-
rane with subsequent expression of CD62P and CD63,
espectively. The negative correlation noted between
D62P expression and pP-selectin suggests expression of
D62P (and its subsequent release in the plasma) results in
epletion of pP-selectin. However, no correlation was noted
etween CD62P and sP-selectin. There can be 3 potential
xplanations for this. First, other than active cleavage or
hedding of platelet membrane-bound P-selectin, there is
vidence that sP-selectin may be released from the
latelets by “direct” secretion (36,37) or passive diffusion
41). Moreover, some contribution from the endothelium is
ossible, although remote (42–44). Second, Ferroni et al.
40), in the setting of cardiopulmonary bypass, reported no
orrelation of CD62P and sP-selectin in view of the
ifferent time course of the rise and fall (normalization) of
hese molecules. Similar lack of correlation between CD62P
nd sP-selectin has been reported in patients presenting
ith acute chest pain (45) and in patients with myocardial
nfarction after thrombolysis (46) leading to suggestions
hat CD62P might reflect platelet activation in response to
cute stimuli, while sP-selectin is a better marker in detect-
ng circulating activated platelets in clinical settings where
ore “chronic” stimuli are present (39). Third, there is also
xperimental evidence to suggest that activated platelets
ight completely loose surface P-selectin, but continue to
unction and circulate (47).
We also found that AF patients whose antithrombotic
herapy was changed from aspirin to warfarin resulted in
eduction in pP-selectin along with nonsignificant reduc-
ions in 3 out of 4 other platelet markers. Aspirin has been
reviously shown to have no significant effect on sP-selectin
evels (48–50), as P-selectin release from platelets is
denosine-diphosphate-dependent and independent of the
yclooxygenase pathway. There are also reports of excess
latelet expression of P-selectin after stimulation by throm-
in receptor-activating peptide (51). Thus, it is possible that
arfarin by reducing circulating thrombin might result in
eduction of overall platelet activation on AF.
Among the different platelet markers, presence of AF
ndependently affected the levels of CD62P expression.
High-risk” AF patients had significantly higher levels of
D62P compared with the “low-risk” patients. Pongratz
t al. (23) has previously reported an association between
igher levels of CD62P with intra-atrial echocardiography
ontrast and thrombus. Whether this is a chance finding or
igher levels of CD62P can truly identify AF patients with
higher stroke risk can only be ascertained in longitudinalollow-up studies.
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